PRIN2017-2017RSAFK7_003-Claudia Desiderio (DCM.AD007.089)

Area tematica

Scienze chimiche e tecnologie dei materiali

Area progettuale

Struttura responsabile del progetto di ricerca

Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC)

Responsabile di progetto

CLAUDIA DESIDERIO
Telefono: 063057612
E-mail: claudia.desiderio@cnr.it

Abstract

The main aims of the project are: 1) to provide a significant advancement in the knowledge of the amniotic secretome; this project will implement high-throughput sequencing and other massively parallel technologies, also known as "omics technologies" (e.g. proteomics, genomics, transcriptomics, lipidomics and metabolomics). Even though each technology individually cannot capture the entire biological complexity, their integration enables a ultiparametric/multimodal profiling of molecules and bioactive factors through a system biology approach. This will be performed both on whole secretome and nano/microvesicle fractions. 2) to develop a suitable delivery system, based on the design of innovative hydrogel-based nanofillers entrapping the secretome, functionalized to achieve a controlled and optimized release in the target tissue. 3) to validate the efficacy of the secretome delivered through innovative nanotechnology in a clinically relevant animal model, represented by spontaneous equine osteoarthritis, a paradigm condition in which immune-related mechanisms are prominently involved and lead to irreversible joint damage.

Obiettivi

ASSEMbLe aims to provide a significant advancement to knowledge on the molecular complexity underlying the anti-inflammatory/immunomodulatory properties of the secretome of mesenchymal stromal cells ement will be implemented in the development of a novel nanotechnology enabling a targeted and controlled release in inflamed tissues. This will be performed through the development of a novel, hydrogel-based injectable matrix.
Osteoaisolated from human term placenta. This will be performed using a multi-omics approach with high throughput technology to determine the bioactive components/fractions of the secretome.This advancrthritis will be tested as the clinical target of this improved cell-free approach, being a paradigm condition in which immune-related mechanisms are prominently involved within the closed complex biological system represented by the joint cavity. The final phase of this project will evaluate the efficacy of the combination of the bioactive fractions and hydrogel nanoparticles in horses with spontaneous osteoarthritis.

Data inizio attività

17/09/2019

Parole chiave

Proteomics, metabolomics and metabonomics, stem cell therapy

Ultimo aggiornamento: 18/08/2025